Burkitt lymphoma and MYC: What else is new?

Advances in Anatomic Pathology

Volumn 21, Issue 3, 2014, Pages 160-165

  Said, Jonathan ^a   Lones, Mark ^a   Yea, Steven ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Burkitt lymphoma; Epstein Barr virus; MYC

Indexed keywords

MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; UBIQUITIN;

B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER MORPHOLOGY; CELL NUCLEUS; CELL PROLIFERATION; CELL VACUOLE; CHROMATIN; CLINICAL FEATURE; CYTOGENETICS; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; IMMUNOPHENOTYPING; ONCOGENE C MYC; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; SIGNAL TRANSDUCTION; CELL TRANSFORMATION; GENE TRANSLOCATION; GENETICS; ONCOGENE MYC; PATHOLOGY;

BURKITT LYMPHOMA; CELL TRANSFORMATION, NEOPLASTIC; GENES, MYC; HUMANS; TRANSLOCATION, GENETIC;

EID: 84898487130     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3182a92cde     Document Type: Review

References (38)

1. Burkitt DP. The discovery of Burkitt's lymphoma. Cancer. 1983;51:1777-1786.
2. Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008;141:840-847.
3. Intermesoli T, Rambaldi A, Rossi G, et al. High cure rates in Burkitt lymphoma and leukemia: NILG study of the German short intensive rituximab-chemotherapy program. Haematologica. 2013. [Epub ahead of print].
4. Leoncini L, Raphael M, Stein H, et al. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Geneva: WHO Press; 2008.
5. Linch DC. Burkitt lymphoma in adults. Br J Haematol. 2012;156:693-703.
6. Smith SM. AIDS-related BL and CD4 count: a clue? Blood. 2010;116:5435-5436.
7. Mbulaiteye SM, Clarke CA, Morton LM, et al. Burkitt lymphoma risk in US solid organ transplant recipients. Am J Hematol. 2013;88:245-250.
8. Bellan C, Lazzi S, Hummel M, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood. 2005;106:1031-1036.
9. Said JW. Aggressive B-cell lymphomas: how many categories do we need? Mod Pathol. 2013;26(Suppl 1):S42-S56.
10. Lones MA, Raphael M, Perkins SL, et al. Mature B-cell lymphoma in children and adolescents: international group pathologist consensus correlates with histology technical quality. J Pediatr Hematol Oncol. 2006;28:568-574.
11. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419-2430.
12. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354:2431-2442.
13. Haralambieva E, Boerma EJ, van Imhoff GW, et al. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol. 2005;29:1086-1094.
14. Boerma EG, Siebert R, Kluin PM, et al. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia. 2009;23:225-234.
15. Poirel HA, Cairo MS, Heerema NA, et al. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non- Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia. 2009;23:323-331.
16. Onciu M, Schlette E, Zhou Y, et al. Secondary chromosomal abnormalities predict outcome in pediatric and adult highstage Burkitt lymphoma. Cancer. 2006;107:1084-1092.
17. Nelson M, Perkins SL, Dave BJ, et al. An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961. Br J Haematol. 2010;148:600-610.
18. Giulino-Roth L, Cesarman E. Molecular biology of burkitt lymphoma. In: Robertson ES, ed. Burkitt's Lymphoma. New York: Springer; 2013:211-226.
19. Klapper W, Szczepanowski M, Burkhardt B, et al. Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood. 2008;112: 1374-1381.
20. Harris NL, Horning SJ. Burkitt's lymphoma-The message from microarrays. N Engl J Med. 2006;354:2495-2498.
21. Lones MA, Sanger WG, Le Beau MM, et al. Chromosome abnormalities may correlate with prognosis in Burkitt/Burkittlike lymphomas of children and adolescents: a report from Children's Cancer Group Study CCG-E08. J Pediatr Hematol Oncol. 2004;26:169-178.
22. Salaverria I, Zettl A, Bea S, et al. Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica. 2008;93:1327-1334.
23. Scholtysik R, Kreuz M, Klapper W, et al. Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. Haematologica. 2010;95:2047-2055.
24. Lenze D, Leoncini L, Hummel M, et al. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia. 2011;25:1869-1876.
25. Dang CV. MYC on the path to cancer. Cell. 2012;149:22-35.
26. Janz S, Potter M, Rabkin CS. Lymphoma- and leukemiaassociated chromosomal translocations in healthy individuals. Genes Chromosomes Cancer. 2003;36:211-223.
27. Sander S, Rajewsky K. Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells. Oncotarget. 2012;3:1066-1067.
28. Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell. 2012;22:167-179.
29. Peled JU, Yu JJ, Venkatesh J, et al. Requirement for cyclin D3 in germinal center formation and function. Cell Res. 2010;20:631-646.
30. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490:116-120.
31. Kwon K, Hutter C, Sun Q, et al. Instructive role of the transcription factor E2A in early B lymphopoiesis and germinal center B cell development. Immunity. 2008;28:751-762.
32. Lin YC, Jhunjhunwala S, Benner C, et al. A global network of transcription factors, involving E2A, EBF1 and Foxo1, that orchestrates B cell fate. Nat Immunol. 2010;11:635-643.
33. Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012;44:1316-1320.
34. De Falco G, Leucci E, Lenze D, et al. Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors. Blood. 2007;110:1301-1307.
35. Villuendas R, Sanchez-Beato M, Martinez JC, et al. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol. 1998;153:887-897.
36. Roberti A, Rizzolio F, Lucchetti C, et al. Ubiquitin-mediated protein degradation and methylation-induced gene silencing cooperate in the inactivation of the INK4/ARF locus in Burkitt lymphoma cell lines. Cell Cycle. 2011;10:127-134.
37. Bedford L, Lowe J, Dick LR, et al. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov. 2011;10:29-46.
38. Ngoma T, Adde M, Durosinmi M, et al. Treatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease. Br J Haematol. 2012;158:749-762.